Through an analysis of tumor samples collected over time from patients with advanced melanoma, a Ludwig Cancer Research study has identified a set of preexisting conditions in tumors that predict whether such patients are likely to respond to a personalized immunotherapy known as adoptive T cell therapy (ACT) using tumor-infiltrating lymphocytes (TIL).
It is with great pleasure that we announce the appointment of Lydia Lynch as a full member of the Princeton Branch of the Ludwig Institute for Cancer Research.
A Ludwig Cancer Research study has generated a granular portrait of how the cellular and molecular components of the blood vessels that feed brain metastases of melanoma and lung and breast cancers differ from those of healthy brain tissue, illuminating how they help shape the internal environment of tumors to support cancer growth and immune evasion.
Ludwig Cancer Research announces its launch of the Ludwig Leadership Fellows Program, which aims to accelerate the careers of exceptional young scientists by helping them establish genuinely independent programs of research immediately after the completion of their graduate studies.
A Ludwig Cancer Research study has for the first time exhaustively analyzed neutrophils that reside in brain tumors, detailing how the immune cells support brain cancer survival and how they’re turned by the tumor microenvironment into enablers of malignant growth.
A Ludwig Cancer Research study has shown that combining adoptive T cell therapy (ACT) with an innovative, personalized cancer vaccine under development at the Lausanne Branch of the Ludwig Institute for Cancer Research can benefit patients with late-stage, drug-resistant ovarian cancer.
In exploring an aspect of how killer T cells generate the raw materials required for their proliferation, a Ludwig Cancer Research study has uncovered an unexpected link between the immune cells’ metabolism, regulation of gene expression, persistence and functional efficacy that could be exploited using existing drugs to improve cancer immunotherapy.
A Ludwig Cancer Research study has identified a pair of genes whose expression by a type of immune cell within tumors is predictive of outcomes for cancer patients and is linked to a vast network of gene expression programs, engaged by multiple cell types in the tumor microenvironment, that control human cancers.
A Ludwig Cancer Research study has discovered that the presence of relatively high numbers of immune cells known as monocytes in tumors is linked to better outcomes in esophageal cancer patients treated with a combination of chemotherapy and immunotherapy, or immunochemotherapy.
Researchers at the Ludwig Center at Harvard have developed a platform technology for imaging that enables integration of the methods of microscopic analysis long employed in pathology laboratories with the visualization of multiple molecular markers in individual cells that is now rapidly advancing in research labs.
Ludwig Cancer Research congratulates Douglas Hanahan, Ludwig Distinguished Scholar at the Lausanne Branch of the Ludwig Institute for Cancer Research, on his election as Foreign Member of the Royal Society.
Two independent Ludwig Cancer Research studies published in the current issue of the journal Cell show that immune cells known as neutrophils, whose abundance in the microenvironment of tumors has traditionally been associated with poor patient prognosis, can play an important role in the success of cancer immunotherapies.
It is with great pleasure that we announce the appointment of Jedd Wolchok and Nicolas Killen to the Board of Directors of the Ludwig Institute for Cancer Research and the LICR Fund, which manages the assets of the Institute.
A Ludwig Cancer Research study has discovered that the immune system’s surveillance of cancer can itself induce metabolic adaptations in the cells of early-stage tumors that simultaneously promote their growth and equip them to suppress lethal immune responses.
A Ludwig Cancer Research study has revealed a single protein expressed at high levels by cancer cells across a broad range of malignancies that erects a multifaceted barrier to anti-cancer immune responses in mouse models of cancer and so shields tumors from immune detection and destruction.
A Ludwig Cancer Research study has developed a novel nanotechnology that triggers potent therapeutic anti-tumor immune responses and demonstrated its efficacy in mouse models of multiple cancers.
A Ludwig Cancer Research study has developed a strategy to noninvasively track immune cells known as macrophages within brain and breast tumors in living mice.
A Ludwig Cancer Research study has identified a combination of three existing drugs that significantly extends survival in mouse models of the lethal brain cancer glioblastoma multiforme (GBM).
Ludwig Cancer Research extends a warm welcome to Pat Morin, who has been appointed deputy scientific director of the Ludwig Institute for Cancer Research.
Though the mutations accumulated by cancer cells occur more or less randomly, certain regions of genes essential to cancer growth appear to be more frequently mutated than others in established tumors.
Ludwig Cancer Research released today the full scope of research to be presented by Ludwig-affiliated scientists at the 2022 American Association for Cancer Research (AACR) Annual Meeting, which will be held online and in person at the Ernest N. Morial Convention Center, in New Orleans, Louisiana, from April 8 to April 13.
Researchers led by Christopher Garcia of the Ludwig Center at Stanford University have solved the long-sought structure of a large signaling protein involved in responses to infection, inflammation, the generation of immune cells and—when dysregulated by mutation—the emergence of blood cancers known as myeloproliferative neoplasms.
A Ludwig Cancer Research preclinical study has demonstrated that a common weight-loss diet could enhance the efficacy of chemotherapy for pancreatic cancer.
A Ludwig Cancer Research study has identified a potential vulnerability in neuroblastoma tumors that might be exploited to improve treatment of the aggressive childhood cancer, which accounts for roughly 15% of all deaths from pediatric malignancies.
A Ludwig Cancer Research study has devised a highly efficient method to generate large numbers of immune cells specifically engineered to recognize neoantigens—small fragments of randomly mutated proteins that are typically unique to a patient’s cancer—and destroy the tumors that express them.
A Ludwig Cancer Research study has uncovered a cellular interaction that is essential to the ability of the immune system’s cytotoxic T lymphocytes to destroy ovarian tumors and shown that its engagement could help determine the efficacy of checkpoint blockade immunotherapy in a variety of cancers.
A Ludwig Cancer Research study has identified a means by which cancer cells engineer the conversion of immune cells known as macrophages from destroyers of tumors to supporters of their growth and survival.
A Ludwig Cancer Research study has identified and preclinically validated combination treatments for the brain metastases of breast cancer, a common and typically lethal manifestation of the malignancy.
A Ludwig Cancer Research study conducted in both mice and a small group of patients with advanced cancers has shown that so-called “cold” tumors that are nearly devoid of immune cells—and therefore unresponsive to immunotherapy—can be turned “hot” with extremely low doses of radiation and the rational use of existing therapies.
It is with great pleasure that we announce the appointment of Mikaël Pittet as a full Member of the Lausanne Branch of the Ludwig Institute for Cancer Research.
A Ludwig Cancer Research study has found that inducing random chromosome instability (CIN) events in mice for as little as one week is enough to trigger harmful chromosomal patterns in cells that spur the formation of tumors.
A Ludwig Cancer Research study adds to growing evidence that immune cells known as macrophages inhabiting the body cavities that house our vital organs can aid tumor growth by distracting the immune system’s cancer-killing CD8+ T cells. Reported in the current issue of Cancer Cell and led by Ludwig investigators Taha Merghoub and Jedd Wolchok at Memorial Sloan Kettering (MSK) and Charles Rudin of MSK, the study shows that cavity-resident macrophages express high levels of Tim-4, a receptor for phosphatidylserine (PS), a molecule that they surprisingly found on the surface of highly activated, cytotoxic and proliferative CD8+ T-cells.
A study conducted by researchers at the Ludwig Center at Harvard has demonstrated how a drug screening method known as dynamic BH3 profiling can be used to quickly identify potentially effective combinations of existing drugs for personalized cancer therapy.
A Ludwig Cancer Research study has discovered how to revive a powerful but functionally inert subset of anti-cancer immune cells that are often found within tumors for cancer therapy. Led by Ludwig Lausanne’s Ping-Chih Ho and Li Tang of the École Polytechnique Fédérale de Lausanne, the study describes how an immune factor known as interleukin-10 orchestrates the functional revival of “terminally exhausted” tumor-infiltrating T lymphocytes (TILs), which have so far proved impervious to stimulation by immunotherapies. It also demonstrates that the factor, when applied in combination with cell therapies, can eliminate tumors in mouse models of melanoma and colon cancer. The findings are reported in the current issue of Nature Immunology.
A Ludwig Cancer Research study has identified a previously unrecognized mechanism by which cancer cells of a relatively benign subtype of pancreatic tumors methodically revert—or “de-differentiate”—to a progenitor, or immature, state of cellular development to spawn highly aggressive tumors that are capable of metastasis to the liver and lymph nodes.
Ludwig Cancer Research is proud to announce on its 50th anniversary the launch of the newest Branch of the Ludwig Institute for Cancer Research.
A Ludwig Cancer Research study has identified a novel mechanism by which a type of cancer immunotherapy known as CTLA-4 blockade can disable suppressive immune cells to aid the destruction of certain tumors.
A study led by Ludwig Chicago Co-director Ralph Weichselbaum and Yang-Xin Fu of the University of Texas Southwestern Medical Center has shown how bacteria in the gut can dull the efficacy of radiotherapy, a treatment received by about half of all cancer patients.
Researchers led by Ludwig San Diego Member Don Cleveland and Peter Campbell of the Sanger Center have solved the mystery of how free-floating circular DNA fragments, which are almost exclusively found in cancer cells, drive gene amplification to generate drug resistance in cancer.
Ludwig Cancer Research is proud to announce that the Lausanne Branch of the Ludwig Institute for Cancer Research has received a Team Science Award from the Society for Immunotherapy of Cancer (SITC).
Ludwig Cancer Research scientists have developed a method to significantly improve the preclinical evaluation of chimeric antigen-receptor (CAR) T cell therapies, in which the immune system’s T cells are extracted from a patient, engineered to target a specific tumor-associated molecule and then grown and reinfused for cancer treatment.
A Ludwig Cancer Research study has uncovered a mechanism by which the tumor’s harsh internal environment sabotages T lymphocytes, leading cellular agents of the anticancer immune response.
Researchers led by Ludwig Chicago Co-director Ralph Weichselbaum and Ronald Rock of the University of Chicago have identified in preclinical studies a potential drug target for curtailing cancer metastasis.
A Ludwig Cancer Research study has identified a new instance in which the simultaneous mutation of two nonessential genes—neither of which is on its own vital to cell survival—can cause cancer cell death.
A Ludwig Cancer Research study has dissected how radiotherapy alters the behavior of immune cells known as macrophages found in glioblastoma (GBM) tumors and shown how these cells might be reprogrammed with an existing drug to suppress the invariable recurrence of the aggressive brain cancer.
Ludwig Cancer Research welcomes Juanita L. Merchant to the Scientific Advisory Committee of the Ludwig Institute for Cancer Research.
It is with great pleasure that Ludwig Cancer Research announces the appointment of Yang Shi as Member of the Oxford Branch of the Ludwig Institute for Cancer Research.
A Ludwig Cancer Research study has profiled, in a sweeping comparative analysis, the distinct immune landscapes of tumors that arise in the brain, or gliomas, and those that metastasize to the organ from the lungs, breast and skin.
Ludwig Cancer Research extends its congratulations to Xin Lu, director of the Oxford Branch of the Ludwig Institute for Cancer Research, on her election to the Fellowship of the Royal Society.
A Ludwig Cancer Research study has discovered a novel means by which bacterial colonies in the small intestine support the generation of regulatory T cells—immune cells that suppress autoimmune reactions and inflammation.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right